Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198
This study is recruiting at 3 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Solid Tumor
- Small Cell Lung Cancer (SCLC)
- High Grade Neuroendocrine Cancer
- Small Cell Carcinomas of Non-lung Origin
- Non-small Cell Lung Cancer (NSCLC)
- Prostate Cancer
- Ovarian Cancer
- Renal Carcinoma (Clear and Non-clear Cell)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Hepatic Cancer
- Gastric Cancer
- Triple-negative Breast Cancer (TNBC)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Last updated on ClinicalTrials.gov
- June 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Start Lacn · Los Angeles, CA
Texas · 1
- START Dallas · Fort Worth, TX
Utah · 1
- START Mountain Region · West Valley City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.